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Nanomaterials are employed in extensive variety of commercial products such as electronic components, cosmetics,
food, sports equipment, biomedical applications, and medicine. With the increasing utilization of engineered
nanomaterials, the potential exposure of human to nanoparticles is rapidly increasing. Nowadays when new
nanomaterials with new applications are introduced, mostly good and positive effects are mentioned whereas
possible hazards arising from nanosize of the compounds are undermined. Toxicology studies of nanomaterials
demonstrate some adverse effects in some human organs such as central nerve system, immune system, and lung.
There is lack of complete information about human toxicity and environmental waste of nanomaterials. We aimed to
highlight current toxicological concerns of potentially useful nanomaterials which are now used in pharmaceutical and
biomedical sciences.
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ability to manipulate matter at the nanoscale, making new
materials, products, and devices that demonstrate new
and unique behavior. Despite this explosive growth, the
potential safety risks associated with consumer products
containing nanoscale materials are still being learned. Ex-
posure to products containing nanomaterials may cause
effects which differ from those observed with convention-
ally scaled materials. Nowadays when new nanomaterials
with new applications are introduced, mostly good and
positive effects are mentioned whereas possible hazards
arising from nanosize of the compounds are undermined.
In addition to the chance of direct exposure to nanocom-
pounds if used in human as a medicine, there are concerns
on exposure during product manufacturing or through
waste sources. Development of nanomaterials with numer-
ous industrial applications such as electronic components,
medical devices, tires, food and beverage, pharmaceuticals,
and cosmetics has increased the chance of accumulation
in the environment and consequent entering into food
chain and human body (Figure 1) [1,2]. As an example,
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formulated with nanosized ingredients (http://www.tga.gov.
au/; accessed June 17, 2014). Also, several new products
containing nanoparticles are being launched by food indus-
tries with the understanding to improve appearance, effi-
ciency, and packaging of foods [3]. For instance, ZnO and
MgO nanoparticles due to their antibacterial activities are
used as the additive to polymer matrix of food packing [4].
On the other hand, there has been progressive interest in
the pharmaceutical companies to use nanomaterials with
the aim to better drug delivery. In this way, some drugs
have got approval for use in human such as Doxil® known
as one of several nanoparticle formulations of doxorubicin
or Abraxane® that is an albumin-based nanoparticle formu-
lation of paclitaxel used to treat different kinds of cancers
and acquired immunodeficiency syndrome. Poly ethylene
glycol (PEG)-linked proteins also represent an important
group of therapeutic macromolecules that have been widely
investigated within the context of nanoparticles. Covalent
attachment of PEG to proteins has been demonstrated to
prolong their circulation due to the size of molecule and re-
duced kidney clearance. Oncospar®, Pegasys®, and Neulasta®
are approved by FDA as PEGylated protein for acute
lymphoblastic leukemia, hepatitis C, and neutropenia, re-
spectively. Macugen® (Pegaptanib) is an approved nanos-
caled formulation of aptamer applied as an antagonist to
vascular endothelial growth factor that lessens growth of
the vessels located within the eye (Table 1) [5]. Besides thetral Ltd.; licensee BioMed Central Ltd. This is an Open Access article distributed
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Figure 1 Percent of various consumer products containing nanomaterials (a), percentage of articles published in scientific journals
addressing the application of nanoparticles in various diseases (b), based on data obtained from Consumer Products Inventory
[http://www.nanotechproject.org/] and Scopus (accessed June 17, 2014).
Table 1 Some of clinically available nanoparticle containing drugs
Trade name Nanomaterial Company Application
Abraxane Albumin Abraxis Oncology Cancer treatment
Basulin Polyglutamate polymer dotted with insulin Advanced Magnetics Type I diabetes
Biovant Nanosized calcium phosphate BioSante Pharmaceuticals Vaccine component
Combidex Iron oxide nanoparticles Advanced Magnetics Tumor imaging
Doxil PEGylated liposome Orthobiotech Cancer treatment
Oncospar PEGylated asparaginase Medac GmbH Leukemia treatment
Opaxio™ Polyglutamic acid Cell Therapeutics, Inc. Cancer treatment
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of human life, concerns on potential adverse human
health effects of nanoparticles are escalating. Intravenous
and subcutaneous injections of nanomaterial-based car-
riers delivers exogenous nanoparticles into the body with
the aim to better distribution whereas broader spread may
cause toxicity and undesirable interaction with biological
macromolecules. Injected nanomaterials smaller than
100 nm are efficiently transported via interstitial flow to
the draining lymphatics and lymph nodes. Meanwhile,
they can reach most of organs dependent on the size of
particle and surface characteristics. Besides injection, other
routs of exposure like dermal, inhalation, and ingestion
are also common. The penetration to skin by use of cos-
metics with nanoparticles is the most relevant dermal
route of exposure in human. Studies show that metallic
nanoparticles smaller than 10 nm are able to penetrate
the epidermal layers [1,6]. Larese et al. [7] demonstrated
the permeation of silver nanoparticles through the
stratum corneum of damaged skin in an in vitro diffu-
sion cell system. Nanoparticles possess the ability to
induce lung inflammation by not only stimulating pul-
monary epithelial cells to generate proinflammatory cy-
tokines, but also via causing endothelial cells to produce
leukocyte adhesion molecules and circulating leuko-
cytes [8]. Non-surprisingly destructive effects of metal
containing nanomaterials on the brain vasculature have
grown the toxicity concerns. For instance, it has been
demonstrated that silver nanoparticles disrupt blood
brain barrier and cause neuronal degeneration [9]. A
major challenge in drug delivery is to improve selective
targeting and safe strategies but major caution should
be made in especial group of patients like pregnant
women, infants, and aged people. Giving examples
about pregnant group, studies have shown that nano-
particles can easily cross the placental barrier and in-
duce pregnancy complications [10] that is a serious
matter. A toxicology study carried out on pregnant mice
investigated the effect of fullerene solubilized with poly
(vinylpyrrolidone) in water when injected intraperitone-
ally to pregnant mice at varying concentrations. The re-
sults demonstrated that fullerene nanoparticles were
traced in the embryos and at higher doses caused sig-
nificant toxicity and death [11]. In addition, titanium
oxide nanoparticles, which are widely used in consumer
products, possess the ability to transfer from pregnant
mice to their offspring affecting the central nerve and
genital systems [12].
Using nanoparticles in medicine and drug delivery is
growing rapidly while there are still non-resolved con-
cerns about their risk of toxicity. It should not be forgot-
ten that every material with smaller size can cross the
cell membrane easier than materials with normal size.
As a matter of fact, most of information about kineticsof materials come from tests of materials in the normal
size and non-surprisingly there is a lack of data about
kinetics of nanosized materials that has a major role in
toxicity [13,14]. Graphene is a good example of a new
nanomaterial that has raised new toxicological con-
cerns [2]. Concerns on the use of nanomaterials also
back to their waste in the environment. At the moment
there is lack of information about pattern of accumula-
tion of nanomaterials waste and their possible entrance
into food chain. Here the facility of in-silico toxicology
should come into help [15]. Therefore, scientists need
a databank of biological effects, toxicity, biokinetics, as
well as structure and molecular size of nanomaterials
to be able to predict their toxicity. In other words,
current need is to estimate different physical and
chemical properties of the nanomaterials relevant to
toxicity, environmental fate, and transport.
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